Glaucoma | Ophthalmology Innovation Source

Mati Therapeutics

Mati is developing a punctal plug drug delivery technology for sustained drug delivery using an “L-shaped” design to deliver medications to the canalicular space. Insertion is via slit lamp, with only the initial procedure requiring patient dilation. The company’s device separates itself from others in that there is a one-directional drug flow out of the…

Graybug

Graybug is developing injectable controlled-release technologies to allow dosing once every four to six months for the treatment of neovascular age-related macular degeneration (AMD), thereby reducing patient burden from 20+ injections yearly to two to three injections. The company is planning to file an Investigational New Drug application before year-end. Graybug licensed the simple, particle…

Brent Saunders, President & CEO of Allergan

Brent Saunders delivers a data-packed presentation about the state of innovation in the life sciences industry and discusses where ophthalmology fits into Allergan’s future. Participant: Brent Saunders Brent Saunders has served as CEO and President of Allergan, formerly Actavis, since July 1, 2014. Previously, Mr. Saunders served as CEO and President of Forest Laboratories from…

Transcend Medical

The year 2015 represented a milestone for Transcend Medical – it completed a milestone study and filed a Premarket Approval for a minimally invasive glaucoma surgery (MIGS) device, the CyPass Micro-Stent. The CyPass is a next-generation device designed to enhance aqueous outflow to the suprachoroidal space by being placed in the supraciliary space (an ab…

Transcend’s Move Toward PMA

Well, the MIGs market could get a little more crowded. This week, Transcend Medical announced it had submitted the final module of its PMA application for the CyPass Micro-Stent, an implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma. FDA approval, which likely won’t come until next year at the earlier,…

FDA Making the Rounds in Ophthalmology

Over the past week, news about the FDA has been flooding the inboxes of ophthalmology watchers. The most notable news came Shire plc. The regulatory agency requested that Shire conduct an additional clinical trial as part of a complete response letter for the company’s NDA for lifitegrast, a potential treatment for dry eye disease in…

Implandata’s Hands-On Approach To Tracking IOP

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 059″] Implandata Ophthalmic Products GmbH is putting the task of tracking intraocular pressure into the hands of patients. Company Co-Founder and General Manager Max G. Ostermeier shares the story of EyeMate, an implantable micro sensor capable of measuring absolute intraocular pressure continuously or on demand. Podcast Guest Max G. Ostermeier, MBA…

Sadri: How MIGS And Other New Tech May Change His Practice

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 058″] Ehsan Sadri, MD, FACS, FAAO discusses the impact MIGS will have on ophthalmology practices and offers his insights on how ophthalmologist will handle pressure from Obamacare and other external forces going forward. Transcript: Tom Salemi: Hi, everyone. This is Tom Salemi. I am the host of the OIS Podcast which…

Aquesys’ CEO Details Allergan’s Successful Bid

Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However, the decision to sell the privately held MIGS company to the Allergan speaks much more directly to the kind of home Allergan will be for XEN Gel Stent, Aquesys’ entry…

Newer glaucoma medication classes about to be a reality?

While our podcast this week examines the rise of Glaukos and the MIGs market, contributor Michelle Dalton presents a State of the Glaucoma Drugs address. With no new classes of drugs to treat glaucoma introduced since the mid-1990s, clinicians and Wall Street are waiting for the next “big thing” to hit the market. Reuters places…

CEO Tom Burns Has Even Bigger Plans For Glaukos

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 052″] MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already commanding reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in venture capital to the company.…

Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

OIS Hot Shot Glaukos Corp. (NASDAQ—GKOS) raised over $100 million in an initial public offering (IPO) that highlighted extraordinary demand for ophthalmology’s minimally invasive glaucoma surgery (MIGS) market leader. In its initial SEC filing, Glaukos had proposed selling 5.4 million shares in the range $13 to $15 per share. With a positive investor reaction during…